Bloomsbury Genetic Therapies

Bloomsbury Genetic Therapies is a clinical-stage biotechnology company dedicated to developing potentially curative gene therapies for rare neurological and metabolic diseases. Leveraging clinically proven AAV gene therapy technologies spun out from University College London (UCL), the company aims to build a portfolio of first- or best-in-class treatments for conditions with high unmet medical needs. It launched in October 2022 with funding from the UCL Technology Fund.